Revealing eltrombopag's promotion of human megakaryopoiesis through AKT/ERK-dependent pathway activation.

ABSTRACT: Eltrombopag is a small, non-peptide thrombopoietin mimetic that has been approved for increasing platelet count not only in immune thrombocytopenia and Hepatitis C virus-related thrombocytopenia, but also in aplastic anemia. Moreover, this drug is under investigation for increasing platelet counts in myelodysplastic syndromes. Despite current clinical practice, the mechanisms governing eltrombopag's impact on human hematopoiesis are largely unknown, in part due to the impossibility of using traditional in vivo models. To investigate eltrombopag's impact on megakaryocyte functions, we employed our established in vitro model for studying hematopoietic stem cell differentiation combined with our latest 3-dimensional silk-based bone marrow tissue model. Results demonstrated that eltrombopag fa

SUBMITTER: Di Buduo CA 

PROVIDER: S-EPMC5479602 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature